Patient and hospital characteristics associated with ticagrelor uptake in acute MI: An analysis of the Chest Pain–MI Registry

ACC/AHA guidelines support the use of the P2Y12 inhibitors clopidogrel, prasugrel, or ticagrelor in acute myocardial infarction (AMI). Little is known about trends in P2Y12 inhibitor selection over time. Multicenter, longitudinal analysis of patients and hospitals in the National Cardiovascular Data...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2020-04, Vol.304, p.14-20
Main Authors: Rodwin, Benjamin A., Lu, Di, Giaimo, Antonio, Annapureddy, Amarnath, Daggubati, Ramesh, Curtis, Jeptha, Sciria, Christopher T., Wang, Tracy Y., Desai, Nihar R.
Format: Article
Language:English
Subjects:
Chest Pain
Hospitals
Humans
Myocardial Infarction - diagnosis
Myocardial Infarction - drug therapy
Myocardial Infarction - epidemiology
Percutaneous Coronary Intervention
Platelet Aggregation Inhibitors
Prasugrel Hydrochloride
Purinergic P2Y Receptor Antagonists
Registries
Ticagrelor
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ACC/AHA guidelines support the use of the P2Y12 inhibitors clopidogrel, prasugrel, or ticagrelor in acute myocardial infarction (AMI). Little is known about trends in P2Y12 inhibitor selection over time. Multicenter, longitudinal analysis of patients and hospitals in the National Cardiovascular Data Registry (NCDR) Chest Pain – MI Registry from the third quarter of 2013 to the first quarter of 2017. A total of 362,354 AMI patients treated at 801 hospitals were included in our analysis. Ticagrelor use increased over time, from 6.1% in 2013 to 33.7% in 2017, with corresponding reductions in the use of clopidogrel and prasugrel (p 
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2020.01.029